Wyeth OTC Loratadine Launch Unaffected By ANDA Exclusivity Issues – Exec
This article was originally published in The Tan Sheet
Executive Summary
Wyeth Consumer Healthcare, which reported sluggish third quarter sales, could experience a big revenue boost late in Q4 if its plans to launch OTC loratadine upon expiration of Schering-Plough's patent remain on track
You may also be interested in...
Wyeth OTC loratadine
Company says it holds "first to file" ANDA status for orally disintegrating loratadine (Schering's Claritin Reditabs). Wyeth also has a pending 505(b)(2) application for OTC sale of the product. Firm recently told analysts Alavert launch would not be sidelined for six months by exclusivity issues (1"The Tan Sheet" Oct. 28, 2002, p. 4)...
Claritin “Market Transition Period” Will Entail Rx Sales Post-OTC Approval
Schering-Plough plans to continue marketing Rx Claritin during a "transition period" following FDA approval of an OTC version of the allergy remedy
Medtech Denorex “Deep Down Dandruff Relief” Ads Debuting In November
Medtech Products will launch a multi-million-dollar ad campaign in November to reacquaint dandruff sufferers with Denorex medicated shampoos and conditioners